Clinical Trial Update: Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) [Phase 2]

View source ↗

Summary

Phase II trial comparing decitabine versus azacitidine in myelodysplastic syndrome has completed; results were posted on 2025-08-07.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Dacogen (decitabine)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2025-08-07